# Anaveon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anaveon

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.anaveon.com
- Total disclosed funding: $154M
- Latest round: Series B (Dec 16, 2021)
- Investors on record: 6

## About

Anaveon AG is a Swiss biotech company focused on developing innovative immunotherapies targeting significant medical needs in oncology and autoimmune diseases, with advanced therapies designed to enhance immune response.Founded in 2017 in Basel, Switzerland, Anaveon AG specializes in immunotherapy development. The company has undergone strategic evolution, focusing on pioneering cancer treatment innovations. It has successfully completed three funding deals, with the latest being a Series B round in December 2021, raising CHF 110 million, led by Forbion and supported by investors including Cowen Investment Management and Pfizer Venture Investments.Anaveon AG specializes in the development of innovative immunotherapies aimed at addressing significant medical needs in oncology and autoimmune diseases. The company's core product offerings include ANV419, a lead immunotherapy candidate designed specifically for cancer treatment, which entered clinical trials in 2021, and ANV600, a bispecific molecule initiated into first-in-human trials in 2024. These compounds aim to orchestrate immune responses through advanced protein engineering, targeting high unmet needs in patient populations. Anaveon's products are primarily directed towards healthcare providers and institutions globally, including markets in Europe and North America, with a focus on oncology clinics, academic research centers, and specialized healthcare facilities. The end users of these therapies are patients suffering from cancer and other immunological disorders, reflecting Anaveon's commitment to transforming scientific insights into practical, life-changing treatments.Anaveon AG has successfully secured over 146 million CHF in funding since its inception in 2017, reflecting the strong support from high-profile investors and its potential for significant market impact. The company's revenue model is built upon partnerships with healthcare providers and research institutions for clinical trials and product development, as well as potential future sales of its proprietary therapies once they receive regulatory approval. Transactions typically occur through structured agreements with pharmaceutical partners, characterized by milestone payments and profit-sharing arrangements associated with the development and commercialization of its flagship products, such as ANV419 and ANV600. While specific pricing plans for these therapies have not been disclosed, the focus remains on establishing robust partnerships that facilitate the advancement of their therapeutics into the market.In December 2021, Anaveon AG raised CHF 110 million in Series B funding led by Forbion, with participation from other investors including Cowen Investment Management, Pfizer Venture Investments, and Pontifax Venture Capital. This financing will be utilized to progress its drug candidate ANV419 through clinical trials and to expand its pipeline into new indications. The company aims to enhance its product offerings and is focusing on expanding into new markets across Europe and North America. The strategic utilization of recent funds will support these initiatives, facilitating advancements in immunotherapy and addressing broader healthcare needs.

## Funding rounds

- Series B, Dec 16, 2021, $119M — Novartis Venture Fund, Forbion, Pontifax Venture Capital, Pfizer Venture Investments, Syncona, Cowen Investment Management
- Series A, Feb 26, 2019, $35M — Novartis Venture Fund, Syncona

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A, Series B
- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B
- Pontifax Venture Capital (https://capitalatlas.ai/funds/pontifax-venture-capital) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Cowen Investment Management — Series B